|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
IRCT |
|
Last refreshed on:
|
22 February 2018 |
|
Main ID: |
IRCT2016100430130N1 |
|
Date of registration:
|
2016-12-03 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
The effect of intravitreal adalimumab injection on pseudophakic macular edema
|
|
Scientific title:
|
The effect of intravitreal adalimumab injection on pseudophakic macular edema |
|
Date of first enrolment:
|
2016-10-16 |
|
Target sample size:
|
5 |
|
Recruitment status: |
Complete |
|
URL:
|
http://en.irct.ir/trial/24038 |
|
Study type:
|
interventional |
|
Study design:
|
Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Iran (Islamic Republic of)
| | | | | | | |
|
Contacts
|
|
Name:
|
Doctor Mohsen Farvardin
|
|
Address:
|
Shiraz University of Medical Sciences central building, Zand BLVD, Shiraz,
Shiraz
Iran (Islamic Republic of) |
|
Telephone:
|
+98 71 3230 5410 |
|
Email:
|
farvardm@sums.ac.ir |
|
Affiliation:
|
Shiraz University of Medical Sciences |
|
|
Name:
|
Doctor Mohsen Farvardin
|
|
Address:
|
Shiraz University of Medical Sciences central building, Zand BLVD, Shiraz,
Shiraz
Iran (Islamic Republic of) |
|
Telephone:
|
+98 71 3230 5410 |
|
Email:
|
farvardm@sums.ac.ir |
|
Affiliation:
|
Shiraz University of Medical Sciences |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: Inclusion criteria: patients with pseudophakic macular edema and PCIOL in bag who have received prior treatment (topical NSAIDs or topical corticosteroids). Exclusion criteria: patients with macular edema due to causes other than pseudophakia(diabetes, uveitis, retinitis pigmentosa); complicated surgery (vitrous loss); PCIOL in sulcus and ACIOL.
Exclusion criteria:
Age minimum:
40 years
Age maximum:
85 years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
Pseudophakic macular edema.
Other specified retinal disorders
|
|
Other specified retinal disorders
|
|
Intervention(s)
|
|
Treatment - Drugs
|
|
intravitreal adalimumab injection
|
|
intravitreal adalimumab injection.
|
|
Primary Outcome(s)
|
|
Visual acuity. Timepoint: Before injection, 1 week and 1 month after injection. Method of measurement: Snellen chart.
|
|
Secondary Outcome(s)
|
|
Central macular thickness. Timepoint: Before injection, 1 week and 1 month after injection. Method of measurement: OCT.
|
|
Source(s) of Monetary Support
|
|
Vice chancellor for research, Shiraz University of Medical Sciences
|
|
Ethics review
|
Status: Approved
Approval date:
Contact:
Shiraz Univercity of Medical Sciences
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|